Posts Tagged :

MRI

Presentation of QUIBIM Precision platform at PARENCHIMA meeting in Prague, October 2018

QUIBIM to manage imaging data and AI for European project PARENCHIMA across 25 countries

QUIBIM has been selected as the main partner to manage all imaging data and analysis algorithms of the PARENCHIMA initiative, a COST action project initiated in April 2017 with the objective of boosting the use of renal MRI biomarkers to improve the management of chronic kidney disease patients. The leading scientific researchers in medical imaging of the kidney from 25 European countries will be using QUIBIM Precision® platform for highly advanced image analysis. One of the challenges of the project is to centralize the medical imaging data and algorithms from all partners to allow for acquisition protocols and algorithms comparison in terms of quality and precision. The outcome of the project will consist of two new standards for image acquisition and analysis in MR of the kidney.

In the past annual meeting of the consortium in Prague, which took place on 4-5 October, an agreement was established between QUIBIM and PARENCHIMA consortium partners for the selection of QUIBIM Precision platform as the best system for images management and integration of new analysis algorithms.

Steven Sourbron, Lecturer in Magnetic Resonance Imaging at the University of Leeds and project coordinator, expressed “I am delighted that QUIBIM has chosen to partner with PARENCHIMA, helping us to improve outcomes for patients by opening up these promising new methods for use in clinical trials and patient management”. Frank Zöllner, adjunct Professor for medical physics at the University of Heidelberg and leader of working group for PARENCHIMA database and software said “QUIBIM has strong expertise in AI algorithms and managing data and we are confident that they are the right collaborator for this project”. Angel Alberich-Bayarri, CEO of QUIBIM said that ”QUIBIM is excited to be part of this project, which will lead to new standards of image acquisition and analysis in Chronic Kidney Disease (CKD), an unaddressed clinical scenario. I am confident that the impact of this study will be global and improve lives of millions of patients, since it is a disease affecting 10% of population worldwide”

 

About PARENCHIMA

Renal MRI biomarkers are today underused in research and in clinical practice due to the need for dedicated in-house expertise and development. Transferring solutions to other centres is therefore a challenge, and this leads to a significant duplication of efforts, a lack of standardisation in the methods, and difficulties in comparing results between centres. This also limits commercial exploitation, and hinders the set-up of multi-centre trials or translation into clinical practice.

The overall aim of PARENCHIMA is to eliminate the main barriers to the broader study, commercial exploitation and clinical use of renal MRI biomarkers.

PARENCHIMA will coordinate the research of leading European groups in this area to:

  • improve the reproducibility and standardisation of renal MRI biomarkers;
  • increase their availability by developing an open-access toolbox with software and data;
  • demonstrate biological validity and clinical utility in a prospective multicentre clinical study.

In order to increase the impact of this project we are reaching out to join the efforts. More info at: www.renalmri.org

 

About QUIBIM

QUIBIM is a company from Valencia (Spain) which applies artificial intelligence and advanced computational models to radiological images to objectively measure changes produced by a lesion or by a pharmacological treatment, offering additional quantitative information to the qualitative approach of radiology. QUIBIM technology and services are applied in clinical practice, clinical trials, radiology education and research projects. More info at: www.quibim.com

3D_Full_Low_Both

Assessing the bone quality of your patients is just a few clicks away

Quibim is proud to introduce its new advanced methodolgy to assess bone quality and fracture risk: QTS (Quality of Trabecular Structure). The need for a reliable approach for the characterization of trabecular microarchitecture is evident, as conditions and diseases related to trabecular bone quality and structure are becoming a focal point of precision medicine. Millions of dollars are spent in bone fracture care and prevention, which in many cases represent a grave danger to the patient health. In this scenario, can we rely upon available methods to predict bone fractures? Regrettably, the answer is no. Or so it was. Before we introduce QTS in detail, let’s first review some of the available methods to evaluate fracture risk.

DEXA Bone Mineral Density (BMD) limitations as a fracture predictor are widely known. However, despite its glaring shortcomings it’s still considered as the gold standard in clinical practice. The WHO developed the FRAX tool hoping to improve the low ratio of success of BMD as a predictor, and, while it improves sensibility and specificity assessing fracture risk, it’s still not satisfactory enough for it to be used as a stand-alone predictor in clinical practice or clinical trials.

In an attempt to fill this void in the search of a reliable predictor, new imaging biomarkers that guarantee to provide the needed sensibility and specificity have been developed. Trabecular Bone Score (TBS®) by Medimaps is a fracture risk predictor using DEXA as a source. TBS® performs a gray level analysis (textures) on the DEXA images to determine bone integrity. But, is DEXA adequate for this task? Unlike regular XR, in which it’s possible to assess the trabecular structure, DEXA’s low radiation is not enough for trabeculae differentiation. In addition, DEXA (like XR) represents a 3D structure as a projection onto a plane, losing spatial information.

Other medical imaging modalities are much more adequate for bone analysis and the subsequent fracture risk evaluation. Thanks to advanced computing models, Quibim has developed a new imaging biomarker that uses either magnetic resonance (MR), computerized tomography (CT) or X-ray imaging for a detailed characterization of the trabecular structure. QTS (Quality of Trabecular Structure) by Quibim introduces several advantages over other analysis methods:

  • Real extraction of the trabecular bone microarchitecture: bone volume, trabecular thickness, trabecular separation…
  • Information of the complexity of the structure: fractal analysis
  • 3D spatial information, not only in plane (only CT and MR)
  • 3D reconstruction of the trabecular bone (only CT and MR)
  • Optional mechanical analysis (only CT and MR, with QTS+)
  • QTS Score comprises all this information in a single score for a rapid and accurate characterization of the bone structure.

This groundbreaking analysis method is already available at our cloud web platform: Quibim Precision. Below we detail how to analyze your study in a few simple steps.

Quibim Precision allows the upload of studies in Dicom format. The upload process is easy, intuitive and 100% secure, guaranteeing the patient confidentiality thanks to Quibim’s anonymization and encryption system. The whole process is performed without the need of installing any additional software. To start, click on the green “Upload Study” button to the right of the website.

00

The platform will then ask for Dicom studies selection. With Google Chrome, we can drag and drop the study folder directly to the dotted box. With any other browser, we need to select the Dicom files to be uploaded.

00b

Once the Dicom folders have been selected, Quibim Precision allows the pre-visualization of the study to choose which sequences we wish to upload. In this case, we need a CT, an X-ray or a 3D T1 MR.

After the selection, the files will be anonymized and encrypted. Quibim Precision will ask for an encryption password before the upload process starts. The user needs to preserve this password, as it’s needed for patient traceability.

00c

After the upload process is completed, we click on the “Analyze Study” button of the study we want to evaluate.

01

This will take us to the detailed view of the study, where we can perform all actions related to it. First of all, we will choose among all the available sequences the one to be analyzed and its Quibim standard name. In this case, the name of the sequence is “Linear Attenuation [1/cm] (3035)”, which corresponds to the standard name “High Resolution CT”.

02

Next, we open the embedded Dicom viewer by clicking on “View”. Thanks to this viewer we can draw the ROI that will be used for the analysis. The viewer allows drawing 3D ROIs, first drawing a 2D rectangular ROI, and then selecting the slices on which it should be replicated. Clicking on “Apply” and “Save and go back” will store the ROI and it will be used for the analysis.

04b

Finally, we should choose which analysis method we’ll use among all the available apps in Quibim Precision. In this case we’ll click on the “Start Analysis” button of the “3D Bone microarchitecture – QTS Score” app. The analysis process will then start, and the user doesn’t need to perform any other action than checking the results.

03

The results of the analysis are available on the view of the study. Once the analysis is completed we can check them by clicking on the “View Study” button on the “Processed Biomarkers” section.

05

We can examine the 3D reconstruction images and the numeric results of the extracted imaging biomarkers on the results view. Furthermore, we can download them and the structured report in pdf format, which includes all the generated data in a compact, easy to read way.

06

07b

08

All the benefits of QTS are just a few clicks away. Create an account on Quibim Precision and start offering a real added value with your imaging studies.

Try us for free!

Have you seen the QUIBIM video teaser?

QUIBIM has launched a new video describing the advanced Imaging Biomarkers analysis process performed at our company. From the assistance and consultancy in medical images acquisition (MR, CT, PET, US, X-Ray, …), through image processing and quantification, to the final structured report generation containing the most relevant information for the clinician, researcher or clinical trials CRO companies.